World Respiratory Disorders Market 2009-2024
Expanding patent populations and rising disease prevalence - World Respiratory Disorders Market 2009-2024 shows you where the opportunities lie in respiratory disorders
Respiratory disorder therapies form an important and competitive part of the pharmaceutical market worldwide. There are wide ranges of drugs and therapeutic needs, both acute and chronic. Revenues are high currently, with good potential for sales increases. As the patient population grows and respiratory diseases become more prevalent, the market has the potential for continued growth in many countries and therapeutic areas. World Respiratory Disorders Market 2009-2024 will give you the analytical information that you need to understand current trends and likely future events in this market area.
The years 2009 to 2015 will represent a period of high volatility in the respiratory therapeutics market, as important products face patent expiry and new drugs reach the market. What types of therapeutic agent are likely to enter the market from 2009 onwards, and will they hold the potential to dominate this market? Has the market reached saturation? Where do the opportunities really lie, and what are the main threats in this market? What are the crucial market drivers and restraints? This new report covers these and many other questions for respiratory therapies.
In particular, World Respiratory Disorders Market 2009-2024 discusses prospects for the following product types:
- Combination drugs (Advair/Seretide, Symbicort and Combivent)
- Corticosteroids (Pulmicort, Nasonex/Asmanex and Flovent/Flixotide)
- Leukotriene inhibitors (Singulair)
- Beta-2 agonists (Xopenex, Salamol and Ventolin)
- Antihistamines (Clarinex/Aerius, Allegra/Telfast and Zyrtec)
- Monoclonal antibodies (Synagis and Xolair)
- Other products (Spiriva, Prevnar, Tamiflu and influenza vaccines).
Comprehensive analysis of the respiratory market area
World Respiratory Disorders Market 2009-2024 examines that sector critically, through a comprehensive review of information sources, both primary and secondary. This report provides detailed sales forecasts, discussions of pipeline developments and analyses of commercial drivers and restraints, including a SWOT analysis. There are over 70 tables and figures, 15 chapters and two interviews with experts. The result is a comprehensive market- and industry-centred report, with detailed analyses and informed opinion to benefit your work.
Why you should buy World Respiratory Disorders Market 2009-2024
By buying this report you will receive the following benefits:
- You will receive a review of the existing market for respiratory disorder therapeutics
- You will receive overall revenue forecasts from 2009 to 2024, at market and sub-market level
- You will find out where leading products and companies are heading, with detailed sales forecasts from 2009 to 2024
- You will receive forecast revenues for leading geographical markets
- You will receive expert opinions from original research interviews
- You will receive well-informed analyses of market drivers and restraints, including SWOT analysis for the sector
- You will receive important pipeline information, seeing how present R&D is shaping the future in that market area.
Respiratory disorder drugs hold the potential for further high revenues. There is a great demand for products that provide therapeutic and commercial benefits in this demanding and competitive market. The developing markets of Asia, Latin America and Europe will drive sales increases in particular.
Table of Contents
1 Executive Summary
- 1.1 Aims of this Report
- 1.2 Brief Overview of the Chapters
2 Respiratory Diseases
- 2.1 Overview
- 2.2 Asthma
- 2.2.1 Causes and Triggers of Asthma
- 2.2.2 Increasing Prevalence
- 2.2.3 High Economic Costs
- 2.2.4 Treatments for Asthma
- 2.2.5 Delivery Method - the Inhaler
- 2.3 Chronic Obstructive Pulmonary Disease (COPD)
- 2.3.1 Symptoms of COPD
- 2.3.2 Management of COPD
- 2.3.3 COPD on the Rise
- 2.3.4 The Economic Burden of COPD
- 2.4 Upper Respiratory Infections
- 2.4.1 Cold
- 2.4.2 Influenza
- 2.4.3 Sinusitis
- 2.4.4 Pharyngitis/Tonsillitis
- 2.4.5 Allergic Rhinitis
- 2.5 Major Drug Classes in Treating Respiratory Diseases
- 2.5.1 Combination Drugs
- 2.5.2 Leukotriene Inhibitors
- 2.5.3 Corticosteroids
- 2.5.4 Beta-2 (Adrenoreceptor) Agonists
- 2.5.5 Antihistamines
- 2.5.6 Monoclonal Antibodies
3 World Market 2009-2024
- 3.1 Summary of Key Findings
- 3.2 Leading Company: GlaxoSmithKline
- 3.3 World Sales for Respiratory Disorder Drugs, 2009-2024
- 3.3.1 Combination Drugs: The Most Successful Category
- 3.3.2 Corticosteroids
- 3.3.3 Antihistamines Face Major Challenges
- 3.3.4 Leukotriene Inhibitors: the Dominance of Singulair
- 3.3.5 Beta-2 Agonists: the Safety Concerns
- 3.3.6 Monoclonal Antibodies: Safe from Patent Expiry?
- 3.4 Increased Competition
4 Combination Drugs: The World Market 2009-2024
- 4.1 Leading the Market
- 4.2 GlaxoSmithKline's Advair/Seretide
- 4.2.1 Three Major Challenges
- 4.3 Symbicort: Facing Strong Competition
- 4.3.1 Aiming for a New Market
- 4.3.2 The COPD Indication
- 4.3.3 The SMART Concept
- 4.4 Combivent: Will It Reach Blockbuster Status?
- 4.5 Will the Leading Position Last?
5 Corticosteroids: The World Market 2009-2024
- 5.1 AstraZeneca's Pulmicort Leads the Market
- 5.1.1 Delivery Methods
- 5.1.2 Challenges for Pulmicort: Are They Insurmountable?
- 5.2 Nasonex/Asmanex on the Rise
- 5.3 Flovent/Flixotide - Reached its Peak?
- 5.4 Will Sales of Corticosteroids Continue to Increase?
6 Leukotriene Inhibitors: The World Market 2009-2024
- 6.1 Singulair
- 6.1.1 Competitors from Other Drug Categories
- 6.1.2 Side Effects
7 Beta-2 Agonists: The World Market 2009-2024
- 7.1 Sepracor's Xopenex at the Top
- 7.1.1 Challenges and Competitors
- 7.2 Teva's Salamol and GlaxoSmithKline's Ventolin
- 7.3 Safety Issues and Potential Loss of Market Share
- 7.4 Summary
8 Antihistamines: The World Market 2009-2024
- 8.1 Clarinex/Aerius Leads the Market
- 8.1.1 Challenges for Clarinex
- 8.2 Sanofi-Aventis' Allegra/Telfast
- 8.2.1 Competition and OTC Availability
- 8.3 Zyrtec and Patent Expiry
- 8.4 The Future for Antihistamines
9 Monoclonal Antibodies: The World Market 2009-2024
- 9.1 Synagis: the Sole Blockbuster?
- 9.1.1 Numax: A Follow-On Product
- 9.2 Xolair Shows Steady Growth
- 9.3 Biologicals vs. Chemically-Derived Pharmaceutical Products: the Advantages of Biologicals
- 9.4 A Promising Future
10 Other Key Products: The World Market 2009-2024
- 10.1 Boehringer Ingelheim's Spiriva
- 10.1.1 Safety Concerns and the UPLIFT Trial
- 10.1.2 Competition and Other Restraints
- 10.2 Wyeth's Prevnar
- 10.2.1 Competition and Development
- 10.3 Roche's Tamiflu
- 10.3.1 The Avian Flu Scare
- 10.3.2 Consequences of the 2009 Swine Flu Outbreak
- 10.3.3 Competition for Tamiflu
- 10.4 Influenza Vaccines
11 SWOT Analysis of the Respiratory Market
- 11.1 Principal Drivers for Respiratory Therapeutics
- 11.1.1 Expanding Patient Populations
- 11.1.2 High Economic Cost of Respiratory Diseases
- 11.1.3 Changing Views of Respiratory Disorders
- 11.1.4 Educating the Masses: Understanding the Severity of Respiratory Diseases
- 11.1.5 Management Rather than Cure
- 11.1.6 Lifecycle Management Strategies to Counter Patent Expiry
- 11.1.7 Brand Awareness
- 11.2 Principal Restraints for Respiratory Therapeutics
- 11.2.1 The Threat of Generics
- 11.2.2 Restrictions on Healthcare Costs Favour the Use of Generics
- 11.2.3 Purchasers Hold Increased Bargaining Power
- 11.2.4 Maturation of the Overall Market – How Much of a Challenge?
- 11.3 Summary of Market Drivers and Restraints
12 Geographical Breakdown of the Market
- 12.1 USA
- 12.2 Europe
- 12.3 Emerging markets
- 12.3.1 Russia
- 12.3.2 China
- 12.3.3 India
13 The Respiratory Pipeline
- 13.1 The Lucrative COPD Market
- 13.1.1 Products to Watch
- 13.2 Early Assessment of Asthma
- 13.3 Biologicals
- 13.3.1 Monoclonal Antibodies
- 13.3.2 Products to Watch
- 13.4 Influenza Treatments
- 13.4.1 Towards a Universal Influenza Vaccine
- 13.4.2 Products to Watch
14 Expert Opinions
- 14.1 Dr Janice Reichert
- 14.1.1 The Threat of Biosimilars
- 14.1.2 Further Developmental Trends
- 14.2 Dr Michael Watson
- 14.2.1 Influenza Vaccines Containing M2e
- 14.2.2 The Threat of Mutation
15 Conclusions
- 15.1 High Revenues
- 15.2 Potential for Growth in Emerging Markets
- 15.3 Potential for Growth Through Addressing Unmet Needs
- 15.4 Will Combination Drugs Continue to Dominate?
- 15.5 Future Opportunities for Monoclonal Antibodies
- 15.6 The Road Ahead
List of Tables
- Table 2.1 Respiratory Diseases
- Table 2.2 Causes of Asthma
- Table 2.3 Asthma Triggers
- Table 2.4 Symptoms of COPD
- Table 2.5 Leading Causes of Death, 2004 and 2030
- Table 2.6 Symptoms for Upper Respiratory Infections
- Table 2.7 Month, Year, and Country of Human Avian Flu Cases, January 08-March 09
- Table 3.1 Market Share (%) of the Leading Companies in the Respiratory Therapeutic Area, 2008
- Table 3.2 Sales ($m) for the World Respiratory Disorder Market, 2009-2024
- Table 3.3 Drug Categories, World Sales ($m) and Market Share (%), 2008 and 2014
- Table 3.4 Key Products in the Respiratory Disorder Therapeutic Area, World Sales ($m) and Market Share (%), 2008
- Table 4.1 Combination Drugs, Key Products World Sales ($m), 2008-2014
- Table 4.2 Combination Drugs, Key Products World Sales ($m), CAGR (%) and Market Share (%), 2009, 2014, 2019 and 2024
- Table 5.1 Corticosteroids, Key Products World Sales ($m), 2008-2014
- Table 5.2 Corticosteroids, Key Products World Sales ($m), CAGR (%) and Market Share (%), 2009, 2014, 2019 and 2024
- Table 6.1 Leukotriene Inhibitors, World Sales ($m), 2008-2014
- Table 6.2 Leukotriene Inhibitors, World Sales ($m), CAGR (%) and Market Share (%), 2009, 2014, 2019 and 2024
- Table 7.1 Beta-2 Agonists, Key Products World Sales ($m), 2008-2014
- Table 7.2 Beta-2 Agonists, Key Products World Sales ($m), CAGR (%) and Market Share (%), 2009, 2014, 2019 and 2024
- Table 8.1 Antihistamines, Key Products World Sales ($m), 2008-2014
- Table 8.2 Antihistamines, Key Products World Sales ($m), CAGR (%) and Market Share (%), 2009, 2014, 2019 and 2024
- Table 9.1 Monoclonal Antibodies, Key Products World Sales ($m), 2008-2014
- Table 9.2 Monoclonal Antibodies, Key Products World Sales ($m), CAGR (%) and Market Share (%), 2009, 2014, 2019 and 2024
- Table 10.1 Other Key Products, World Sales ($m), 2008-2014
- Table 10.2 Symptoms of Swine Flu
- Table 10.3 Influenza vaccines, World Sales ($m), 2008-2014
- Table 10.4 Influenza Vaccines, World Sales ($m), CAGR (%) and Market Share (%), 2009, 2014, 2019 and 2024
- Table 11.1 SWOT Analysis for the Respiratory Market, 2009
- Table 12.1 Sales ($m), CAGR (%) and Market Share (%) for Key Geographical Markets, 2008, 2014, 2019 and 2024
List of Figures
- Figure 3.1 Market Share (%) of the Leading Companies in the Respiratory Therapeutic Area, 2008
- Figure 3.2 Sales ($m) for the World Market, 2009-2024
- Figure 3.3 Market Share (%) of Key Drug Categories in the Respiratory Market, 2008
- Figure 4.1 Sales ($m) for Combination Drugs, 2008-2024
- Figure 4.2 Sales ($m) for Advair/Seretide, 2008-2024
- Figure 4.3 Key Products Marked Share (%) Within the Combination Drug Category, 2008
- Figure 4.4 Sales ($m) for Symbicort, 2008-2024
- Figure 4.5 Sales ($m) for Combivent, 2008-2024
- Figure 4.6 Sales ($m) of Key Products in the Combination Drug Category, 2009, 2014, 2019 and 2024
- Figure 5.1 Sales ($m) for Corticosteroids, 2008-2024
- Figure 5.2 Key Product Market Share (%) within the Corticosteroid Category, 2008
- Figure 5.3 Sales ($m) for Pulmicort, 2008-2024
- Figure 5.4 Sales ($m) for Nasonex, 2008-2024
- Figure 5.5 Sales ($m) for Flovent, 2008-2024
- Figure 5.6 Sales ($m) of Key Products in the Corticosteroid Category, 2009, 2014, 2019 and 2024
- Figure 6.1 Sales ($m) for Leukotriene Inhibitors, 2008-2024
- Figure 6.2 Leukotriene Inhibitors, Market Share (%), 2008
- Figure 6.3 World Sales ($m) of Singulair, 2008-2024
- Figure 6.4 Sales ($m) of Key Products in the Corticosteroid Category, 2009, 2014, 2019 and 2024
- Figure 7.1 Sales ($m) for Beta-2 Agonists, 2008-2024
- Figure 7.2 Key Products Marked Share (%) Within the Beta-2 Agonist Category, 2008
- Figure 7.3 Sales ($m) of Xopenex, 2008-2024
- Figure 7.4 Sales ($m) of Salamol, 2008-2024
- Figure 7.5 Sales ($m) of Ventolin, 2008-2024
- Figure 7.6 Sales ($m) of Key Products in the Beta-2 Agonists Category, 2009, 2014, 2019 and 2024
- Figure 8.1 Sales ($m) for Antihistamines, 2008-2024
- Figure 8.2 Antihistamines Market Share (%), 2008
- Figure 8.3 Sales ($m) for Clarinex, 2008-2024
- Figure 8.4 Sales ($m) for Allegra, 2008-2024
- Figure 8.5 Sales ($m) for Zyrtec, 2008-2024
- Figure 8.6 Sales ($m) of Key Products in the Antihistamine Category, 2009, 2014, 2019 and 2024
- Figure 9.1 Sales ($m) for Monoclonal Antibodies, 2008-2024
- Figure 9.2 Key Product Market Share (%) within the Monoclonal Antibody Category, 2008
- Figure 9.3 Sales ($m) for Synagis, 2008-2024
- Figure 9.4 Sales ($m) of Key Products in the Monoclonal Antibody Category, 2009, 2014, 2019 and 2024
- Figure 9.5 Sales ($m) for Xolair, 2008-2024
- Figure 10.1 Sales ($m) for Spiriva, 2008-2024
- Figure 10.2 Sales ($m) for Prevnar, 2008-2024
- Figure 10.3 Sales ($m) for Tamiflu, 2008-2024
- Figure 10.4 Sales ($m) for Influenza Vaccines, 2008-2024
- Figure 12.1 Market Share (%) for Key Geographical Regions, 2008
- Figure 12.2 Sales ($m) for the Respiratory Markets in the US, Europe and E7 Countries, 2009, 2014, 2019 and 2024
Other users found this report page using the following search terms: copd asthma rhinitis Respiratory Influenza airway Corticosteroid Leukotriene Beta-2 lama laba market respiratory 2009 sales drug world 2008 copd share disorders
If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.
Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.